Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 43
Filter
1.
Ned Tijdschr Geneeskd ; 1642020 04 16.
Article in Dutch | MEDLINE | ID: mdl-32324351

ABSTRACT

Cholesteatoma is a mass formed by the keratinizing squamous epithelium in the tympanic cavity and/or mastoid that can lead to the destruction of surrounding structures in the ear. It can arise at any age. Symptoms are non-specific and diagnosis may be difficult on otoscopic examination. The management of cholesteatoma is surgical; mastoid obliteration has reduced the incidence of recurrent cholesteatoma in recent years. The use of diffusion-weighted MRI has proven to be a reliable technique for the detection and follow-up of cholesteatoma.


Subject(s)
Cholesteatoma, Middle Ear/diagnostic imaging , Ear, Middle/diagnostic imaging , Mastoid/diagnostic imaging , Cholesteatoma, Middle Ear/surgery , Diffusion Magnetic Resonance Imaging , Ear, Middle/surgery , Humans , Mastoid/surgery
2.
Am J Crit Care ; 24(5): 450-2, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26330439

ABSTRACT

A young man had severe septic shock with multiorgan failure due to necrotizing fasciitis caused by group A streptococcus after endoscopic repair of a preperitoneal inguinal hernia. He was treated with surgical exploration and antibiotics and resuscitated with fluids, vasopressors, and inotropic agents. He survived this critical illness, but when he woke up from sedation, his vision was lost in both eyes. Ophthalmological evaluation revealed minimal peripapillary retinal hemorrhages without signs of papillary edema. Visually evoked potentials were negative. Magnetic resonance imaging did not show a cause of the visual damage. The patient had bilateral ischemic optic neuropathy diagnosed. Two weeks later, unilateral sudden deafness also developed. The acquired blindness and hearing loss were unchanged after more than 1 year and seem to be permanent, severely disabling this young survivor of septic shock.


Subject(s)
Deafness/etiology , Optic Neuropathy, Ischemic/etiology , Shock, Septic/complications , Adult , Follow-Up Studies , Humans , Male
3.
J Laryngol Otol ; 128(7): 599-603, 2014 Jul.
Article in English | MEDLINE | ID: mdl-25003659

ABSTRACT

OBJECTIVE: To determine the value of non echo planar, diffusion-weighted magnetic resonance imaging for detection of residual and recurrent middle-ear cholesteatoma after combined-approach tympanoplasty. METHOD: The magnetic resonance imaging findings after primary surgery for cholesteatoma were compared with intra-operative findings at 'second-look' surgery or with clinical follow-up findings. RESULTS: Forty-eight magnetic resonance imaging studies were performed in 38 patients. Second-look surgery was performed 21 times in 18 patients. The remaining patients were followed up at the out-patient clinic. There were no false-positive findings with non echo planar, diffusion-weighted magnetic resonance imaging; however, there were four false-negative findings. The mean maximum diameter of recurrent cholesteatoma, as assessed using magnetic resonance imaging, was 11.7 mm (range, 4.4-25.3 mm). The sensitivity of non echo planar, diffusion-weighted magnetic resonance imaging for detecting cholesteatoma prior to second-look surgery was 0.76, with a specificity of 1.00. When clinical follow up of the non-operated ears was included in the analysis, sensitivity was 0.81 and specificity was 1.00. CONCLUSION: Recurrent cholesteatoma can be accurately detected using non echo planar, diffusion-weighted magnetic resonance imaging. Our study, however, also showed some false-negative results. Therefore, strict out-patient follow up is mandatory for those considering using this technique instead of standard second-look surgery.


Subject(s)
Cholesteatoma, Middle Ear/diagnosis , Diffusion Magnetic Resonance Imaging/methods , Echo-Planar Imaging/methods , Adult , Cholesteatoma, Middle Ear/surgery , Female , Follow-Up Studies , Humans , Male , Middle Aged , Postoperative Period , Prospective Studies , Recurrence , Reproducibility of Results
4.
Clin Otolaryngol ; 32(4): 275-82, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17651269

ABSTRACT

OBJECTIVES: The free radial forearm flap has replaced the pedicled pectoralis major myocutaneous flap and it has become the 'workhorse flap' used by many head and neck reconstructive surgeons for soft tissue reconstructions. Cost implications of radial forearm flap reconstruction within the context of the overall health care in a particular system need to be investigated particularly before it is labelled as 'costly only'. DESIGN AND SETTING: Forty patients who underwent immediate free radial forearm flap reconstruction for oral or oropharyngeal soft tissue defects were matched with patients who underwent pectoralis major myocutaneous flap reconstruction for similar defects. The 2 years of which the overall management costs according to the hospital perspective were calculated were divided into four periods: operative period, the postoperative phase, follow-up during first year and follow-up during second year after discharge. RESULTS: The total costs within the first 2 years were comparable at approximately 50,000 Euros. The lower costs of hospital admission (24 days versus 28 days; P = 0.005) in the postoperative phase outweighed the higher costs of the surgical procedure (692 min versus 462 min; P < 0.005) in radial forearm flap patients when compared with pectoralis major flap patients. CONCLUSIONS: Oral and oropharyngeal reconstruction with radial forearm flap is not more costly than pectoralis major flap reconstruction. Given the better functional outcome and the present cost analysis, reconstruction of oral and oropharyngeal defects is preferably performed using free tissue transfer.


Subject(s)
Forearm/blood supply , Head and Neck Neoplasms/surgery , Pectoralis Muscles/blood supply , Pectoralis Muscles/transplantation , Plastic Surgery Procedures/economics , Plastic Surgery Procedures/methods , Surgical Flaps , Aged , Case-Control Studies , Chi-Square Distribution , Costs and Cost Analysis , Female , Humans , Male , Middle Aged , Statistics, Nonparametric , Treatment Outcome
5.
JPEN J Parenter Enteral Nutr ; 30(5): 415-20, 2006.
Article in English | MEDLINE | ID: mdl-16931610

ABSTRACT

BACKGROUND: Thyroid hormone metabolism is modulated by starvation and overfeeding but also by dietary composition. Unfortunately, little is known about the effect of malnutrition on disease-induced nonthyroidal illness (NTI). In this study, we investigated whether the degree of NTI after surgery differed between severely malnourished and well-fed patients with head and neck cancer. METHODS: Plasma levels of the thyroid hormones 3',5-triiodothyronine (T(3)), reverse T(3) (rT(3)), free T(4) (FT(4)), and thyrotropin (TSH) were measured on the first day before the operation and on the first, fourth, and seventh day after the operation in 16 malnourished patients who were admitted for intentional curative surgery of T1-T4 carcinomas of the head and neck. Six well-fed head and neck cancer patients eligible for surgical treatment served as a control group. RESULTS: In the malnourished group, rT(3) showed a significant increase, whereas T(3) and FT(4) decreased significantly due to the operation. TSH showed no significant change. During the postoperative course, it took 7 days until rT(3) and 4 days until T(3) and FT(4) were restored to their preoperative value. In contrast, well-fed patients did not develop NTI. CONCLUSIONS: This study shows that peri- and postoperative rT(3), T(3), and FT(4) levels change significantly in malnourished patients compared with well-fed patients. Therefore, it can be concluded that nutrition status of patients undergoing major head and neck surgery should be optimized in order to prevent the development of NTI.


Subject(s)
Head and Neck Neoplasms/complications , Malnutrition/complications , Thyroid Diseases/epidemiology , Thyroid Hormones/blood , Case-Control Studies , Female , Head and Neck Neoplasms/blood , Head and Neck Neoplasms/surgery , Humans , Male , Malnutrition/blood , Middle Aged , Nutritional Status , Postoperative Period , Prognosis , Prospective Studies , Thyroid Diseases/blood , Thyroid Diseases/etiology , Thyrotropin/blood , Thyroxine/blood , Triiodothyronine/blood , Triiodothyronine, Reverse/blood
6.
J Nucl Med ; 42(9): 1364-7, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11535726

ABSTRACT

UNLABELLED: 186Re-labeled chimeric monoclonal antibody U36 (cMAb U36) was recently evaluated in a phase I dose escalation study in head and neck cancer patients. All 13 patients received 99mTc-labeled cMAb U36 before 186Re-cMAb U36 radioimmunotherapy. The aim of this study was to evaluate the suitability of multiple or limited blood sampling to predict clearance, red marrow absorbed dose, and myelotoxicity of 186Re-cMAb U36. METHODS: Population pharmacokinetics of 186Re-cMAb U36 were analyzed with a nonparametric expectation algorithm (NPEM 2) and used for Bayesian analysis of individual patient data to predict cMAb U36 clearance. RESULTS: 186Re-cMAb U36 clearance was most accurately predicted (r = 0.91, P < 0.001) with limited sampling for sample points 4 and 72 h after administration of 186Re-cMAb U36. These predictions were less accurate with 99mTc-cMAb U36 (r = 0.51, P = 0.078 for multiple sampling; r = 0.47, P = 0.104 for sampling at 4 and 21 h after administration). Thrombocytopenia was found to be correlated with the red marrow absorbed dose and was equally well predicted by limited blood sampling after administration of 99mTc-cMAb U36 (r = 0.81, P < 0.01) or 186Re-cMAb U36 (r = 0.79, P < 0.01). CONCLUSION: Limited sampling seems useful to predict pharmacokinetics and myelotoxicity of 186Re-cMAb U36.


Subject(s)
Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal/pharmacokinetics , Bone Marrow/radiation effects , Head and Neck Neoplasms/radiotherapy , Radioimmunotherapy/adverse effects , Radioisotopes/adverse effects , Radioisotopes/pharmacokinetics , Rhenium/adverse effects , Rhenium/pharmacokinetics , Aged , Algorithms , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/therapeutic use , Area Under Curve , Bayes Theorem , Female , Humans , Male , Middle Aged , Predictive Value of Tests , Radioisotopes/therapeutic use , Radiotherapy Dosage , Recombinant Fusion Proteins , Regression Analysis , Rhenium/therapeutic use , Thrombocytopenia/etiology
8.
Head Neck ; 23(7): 559-65, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11400244

ABSTRACT

BACKGROUND: Despite improvements in locoregional treatment of stages III/IV squamous cell carcinoma of the head and neck (HNSCC), local and distant failure rates remain high. An effective adjuvant therapy is required for these patients. Among novel approaches is radioimmunotherapy, in which monoclonal antibodies (MAbs) are used for selective delivery of radiation to tumor cells. METHODS: The suitability of 186Re-labeled chimeric MAb U36 (186Re-cMAb U36) for radioimmunotherapy was evaluated in a phase I study, with radiation dose escalating steps of 11, 27, and 41 mCi/m2. Tumor targeting was monitored with a gamma camera, and the maximum tolerated dose was established in 13 patients with recurrent or metastatic disease. RESULTS: Administrations were well tolerated, and excellent targeting of tumor lesions was seen. Myelotoxicity was the only toxicity observed, resulting in dose-limiting toxicity in two patients treated with 41 mCi/m2. The MTD was established at 27 mCi/m2. A marked reduction in tumor size was observed in two patients, another showed stable disease for 6 months. CONCLUSIONS: Radioimmunotherapy with 186Re-cMAb U36 seems to be well tolerated, with bone marrow being the dose-limiting organ. The observation of antitumor effects is encouraging for further development of radioimmunotherapy for HNSCC.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Carcinoma, Squamous Cell/radiotherapy , Head and Neck Neoplasms/radiotherapy , Radioimmunotherapy , Aged , Female , Humans , Male , Middle Aged , Neoplasm Recurrence, Local/radiotherapy , Radioisotopes/pharmacokinetics , Radioisotopes/therapeutic use , Radiotherapy Dosage , Recombinant Fusion Proteins , Rhenium/pharmacokinetics , Rhenium/therapeutic use , Tomography, Emission-Computed, Single-Photon
9.
Am J Clin Nutr ; 73(2): 323-32, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11157331

ABSTRACT

BACKGROUND: Malnourished head and neck cancer patients are at increased risk of postoperative complications. OBJECTIVE: We studied the effect of perioperative, arginine-supplemented nutritional support on nutritional status, immune status, postoperative outcome, and survival in severely malnourished (weight loss >10% of body weight) head and neck cancer patients undergoing major surgery. DESIGN: Forty-nine patients were randomly assigned to receive 1) no preoperative and standard postoperative tube feeding, 2) standard preoperative and postoperative tube feeding, or 3) arginine-supplemented preoperative and postoperative tube feeding. RESULTS: Patients in both prefed groups received approximately 9 d of preoperative tube feeding, resulting in energy intakes of 110% and 113% of calculated needs (compared with 79% in the control group; P = 0.007). Compared with no preoperative feeding, preoperative enteral nutrition did not significantly improve nutritional status or any of the studied biochemical or immunologic indexes. Major postoperative complications occurred in 53%, 47%, and 59% of patients in study groups 1, 2, and 3 (NS). A trend was seen toward better survival in the arginine-supplemented group (P = 0.15). Secondary analysis showed that survivors had better human leukocyte antigen-DR expression on monocytes (P = 0.05) and higher endotoxin-induced cytokine production (P = 0.010 for tumor necrosis factor alpha and P = 0.042 for interleukin 6) at the start of the study than did patients who died. CONCLUSIONS: Nine days of preoperative tube feeding, with or without arginine, did not significantly improve nutritional status, reduce the surgery-induced immune suppression, or affect clinical outcome in severely malnourished head and neck cancer patients. Patients supplemented with arginine-enriched nutrition tended to live longer. Some markers of immune function may distinguish patients with good or bad prognoses.


Subject(s)
Arginine/therapeutic use , Carcinoma, Squamous Cell/therapy , Head and Neck Neoplasms/therapy , Immune System/physiology , Nutrition Disorders/therapy , Nutritional Status/drug effects , Aged , Arginine/administration & dosage , Carcinoma, Squamous Cell/complications , Carcinoma, Squamous Cell/immunology , Carcinoma, Squamous Cell/mortality , Dietary Supplements , Enteral Nutrition , Female , HLA-DR Antigens/immunology , Head and Neck Neoplasms/complications , Head and Neck Neoplasms/immunology , Head and Neck Neoplasms/mortality , Humans , Immune System/drug effects , Interleukin-6/blood , Male , Middle Aged , Morbidity , Nutrition Disorders/complications , Perioperative Care , Postoperative Care , Prognosis , Survival Analysis , Time Factors , Tumor Necrosis Factor-alpha/analysis , Weight Loss
10.
Otolaryngol Head Neck Surg ; 124(2): 217-21, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11226960

ABSTRACT

BACKGROUND: Intracranial metastases are rarely clinically diagnosed in patients with head and neck squamous cell carcinoma. Only 7 patients with metastases to the cavernous sinus from head and neck squamous cell carcinomas have been reported. METHODS: A retrospective study revealed 13 patients with intracranial metastases of head and neck squamous cell carcinoma. In a 53-year-old woman a cavernous sinus metastasis of a laryngeal carcinoma was histologically diagnosed by using a CT-guided surgical navigation system and was treated with stereotactic radiotherapy. RESULTS: The mean survival was 4.3 months. Predictive factors for longer survival were absence of extracranial disease, age younger than 60 years, and treatment with radiotherapy. CONCLUSIONS: The prognosis for patients with intracranial disease is poor. The current development of computer-assisted stereotactic navigation and stereotactic radiotherapy may facilitate surgical diagnostic exploration and improve treatment, especially in patients without extracranial disease.


Subject(s)
Brain Neoplasms/secondary , Carcinoma, Squamous Cell/secondary , Laryngeal Neoplasms/pathology , Adult , Aged , Brain Neoplasms/therapy , Carcinoma, Squamous Cell/therapy , Combined Modality Therapy , Female , Humans , Hypopharyngeal Neoplasms/pathology , Hypopharyngeal Neoplasms/therapy , Laryngeal Neoplasms/therapy , Magnetic Resonance Imaging , Male , Middle Aged , Nasopharyngeal Neoplasms/pathology , Nasopharyngeal Neoplasms/therapy , Neoplasms, Second Primary/pathology , Neoplasms, Second Primary/therapy , Oropharyngeal Neoplasms/pathology , Oropharyngeal Neoplasms/therapy , Prognosis , Retrospective Studies , Survival Rate
11.
JPEN J Parenter Enteral Nutr ; 24(6): 329-36, 2000.
Article in English | MEDLINE | ID: mdl-11071592

ABSTRACT

BACKGROUND: Patients with advanced stages of head and neck cancer are often characterized by malnutrition and by an impaired immune system. Because some of the suppressed immune parameters were shown to be of prognostic importance in trauma and sepsis, we investigated whether these would also correlate with survival in head and neck cancer. METHODS: Severely malnourished head and neck cancer patients undergoing ablative and reconstructive surgery were followed prospectively and their perioperative immune parameters were related to long-term survival. RESULTS: Forty-nine patients with a preoperative weight loss of more than 10% were followed up for a period of at least 16 months after surgery. Analyses of variance revealed that preoperative human leukocyte antigen-DR (HLA-DR) expression on monocytes and endotoxin-induced production of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) were different between patients who survived and patients who died. Proportional hazards identified a weight loss of more than 12%, the presence of coexistent disease, and an HLA-DR expression on monocytes below the cutoff points (mean fluorescence index < 15, peak channel index < 9) to be of significant influence on survival. CONCLUSIONS: In addition to known prognostic parameters such as tumor stage, coexistent disease, and weight loss, the immune parameters HLA-DR expression on monocytes and endotoxin-induced cytokine production may carry prognostic value in cancer patients. Immunomodulating therapies leading to improvement of these parameters might in the future lead to increased options for treatment.


Subject(s)
HLA-DR Antigens/biosynthesis , Head and Neck Neoplasms/mortality , Interleukin-6/biosynthesis , Monocytes/immunology , Nutrition Disorders/complications , Tumor Necrosis Factor-alpha/biosynthesis , Adjuvants, Immunologic , Female , Head and Neck Neoplasms/complications , Head and Neck Neoplasms/immunology , Head and Neck Neoplasms/surgery , Humans , Male , Middle Aged , Nutrition Disorders/immunology , Prognosis , Prospective Studies , Survival Analysis
12.
Eur J Surg Oncol ; 26(6): 556-60, 2000 Sep.
Article in English | MEDLINE | ID: mdl-11034805

ABSTRACT

BACKGROUND: Early stage squamous cell carcinoma of the base of the tongue has been successfully treated with radiotherapy and brachytherapy. However, the vast majority of these tumours seen in Western Europe are already at an advanced stage. Medical records of 79 patients with squamous cell carcinoma of the base of the tongue treated between 1980 and 1994 were examined. METHODS: Eighty-three per cent of the primary tumours were stage T3 or T4. Fifty-nine patients were treated with surgery and post-operative radiotherapy. Quality of life assessment amongst the survivors was performed by means of a questionnaire. RESULTS: Five year disease free survival in patients undergoing excision for T3-T4 tumours was 59%. Patients with T2-T3 tumours undergoing partial excision of the tongue base had a 3 year recurrence free survival rate of 68%. Distant metastasis occurred in 16%. Seventy-eight per cent of the patients judged their quality of life to be near normal. CONCLUSION: Surgery and post-operative radiotherapy offer a reasonably good survival in advanced carcinoma of the base of the tongue with preservation of quality of life.


Subject(s)
Carcinoma, Squamous Cell/radiotherapy , Carcinoma, Squamous Cell/surgery , Tongue Neoplasms/radiotherapy , Tongue Neoplasms/surgery , Carcinoma, Squamous Cell/pathology , Combined Modality Therapy , Deglutition , Disease-Free Survival , Female , Humans , Male , Middle Aged , Neoplasm Staging , Postoperative Complications , Quality of Life , Speech , Surgical Flaps , Survival Analysis , Tongue Neoplasms/pathology , Treatment Failure
13.
Clin Cancer Res ; 6(8): 3046-55, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10955783

ABSTRACT

The CD44 protein family consists of isoforms, encoded by standard exons and up to nine alternatively spliced variant exons (v2-v10), which are expressed in a tissue-specific way. Expression of v6-containing variants (CD44v6) has been related to aggressive behavior of various tumor types and was shown to be particularly high in squamous cell carcinoma (SCC). Therefore, CD44v6 might be a suitable target for radioimmunoscintigraphy (RIS) and therapy. The present study evaluates the novel high-affinity murine anti-CD44v6 monoclonal antibody (MAb) BIWA 1 for its safety and targeting potential in patients with SCC of the head and neck (HNSCC). Twelve HNSCC patients, who had planned to undergo resection of the primary tumor and neck dissection, were included. Preoperatively, 2, 12, or 52 mg of 99nTc-labeled MAb BIWA 1 was administered. RIS results obtained 21 h after injection were compared with palpation, computed tomography, and magnetic resonance imaging, with histopathology as the gold standard. Moreover, biodistribution of BIWA 1 was evaluated by radioactivity measurement in blood and bone marrow and in biopsies from the surgical specimen obtained 40 h after injection. The distribution of BIWA 1 in tumor biopsies was analyzed by immunohistochemistry. BIWA 1 integrity in the blood was assessed by high-performance liquid chromatography and related to soluble CD44v6 levels in serum samples. No drug-related adverse events were observed. Human antimouse antibody responses were observed in 11 patients. The diagnostic efficacy of RIS appeared to be comparable for the three BIWA 1 dose levels and for the four diagnostic methods. Besides activity uptake in tumor tissue, minimal accumulation of activity was observed in mouth, lungs, spleen, kidney, bone marrow, and scrotal area. Analysis of tissue biopsies revealed high uptake in tumors, with a mean value of 14.2+/-8.4% of the injected dose/kg tumor tissue and a mean tumor:blood ratio of 2.0+/-1.4 at 40 h after injection. Differences among the three dose groups were not statistically significant, although a trend toward lower uptake in the highest dose group was noted. Distribution of BIWA 1 throughout the tumor was heterogeneous for all dose groups, which might be related to the high affinity of the MAb. The mean biological half-life in blood (34.5+/-6.1 h) was not dose dependent. Extensive complex formation of BIWA 1 was observed in the 2-mg group, most probably with soluble CD44v6 present in the blood, and complex formation relatively diminished upon increase of the MAb dose. BIWA 1 is a promising MAb for targeting HNSCC because it can be safely administered to HNSCC patients, while it shows high and selective tumor uptake. However, BIWA 1 is immunogenic, and therefore a chimerized or humanized derivative of BIWA 1 with intermediate affinity will be used in future clinical trials.


Subject(s)
Antibodies, Monoclonal/adverse effects , Carcinoma, Squamous Cell/metabolism , Glycoproteins/immunology , Head and Neck Neoplasms/metabolism , Hyaluronan Receptors/immunology , Immunoconjugates/adverse effects , Immunoconjugates/pharmacokinetics , Radiopharmaceuticals/adverse effects , Radiopharmaceuticals/pharmacokinetics , Technetium , Adult , Aged , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/pharmacokinetics , Antibodies, Neoplasm/blood , Carcinoma, Squamous Cell/diagnostic imaging , Carcinoma, Squamous Cell/immunology , Female , Head and Neck Neoplasms/diagnostic imaging , Head and Neck Neoplasms/immunology , Humans , Immunohistochemistry , Male , Middle Aged , Radioimmunodetection , Technetium/adverse effects , Technetium/pharmacokinetics , Tissue Distribution
14.
Clin Nutr ; 19(6): 437-44, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11104595

ABSTRACT

BACKGROUND AND AIMS: This study evaluated the use of perioperative nutritional support on Quality of Life (QOL) in malnourished head and neck cancer patients undergoing surgery. METHODS: 49 Malnourished (weight loss >10%) head and neck cancer patients who were included in a nutrition intervention trial were randomized to receive either no preoperative and standard postoperative tube-feeding (group I), standard preoperative and postoperative tube-feeding (group II) or arginine-supplemented preoperative and postoperative tube-feeding (group III). Of these patients, 31 completed a full QOL assessment on the first day of preoperative nutritional support, one day before surgery, and 6 months after surgery. Both a disease-specific (EORTC QLQ-C30) and a generic questionnaire (COOP-WONCA) were used. One way analysis of variance (ANOVA) and the Kruskal-Wallis test were applied for testing differences in scores between groups. RESULTS: Between baseline and the day before surgery, both preoperatively fed groups revealed a positive change for the dimensions physical and emotional functioning and dyspnea (with significance in group II, P=0.050,0.031,0.045 respectively). Group III showed a negative change in appetite (P=0.049). Between baseline and 6 months after surgery, there were no differences between group I and both pre-fed groups. There were no differences in favour of group III compared to group II. CONCLUSION: Enteral nutrition improves QOL of severely malnourished head and neck cancer patients in the period preceding surgery. No benefit of preoperative enteral feeding on QOL could be demonstrated 6 months after surgery.


Subject(s)
Enteral Nutrition , Head and Neck Neoplasms/complications , Nutrition Disorders/therapy , Perioperative Care , Quality of Life , Adult , Aged , Aged, 80 and over , Analysis of Variance , Female , Head and Neck Neoplasms/surgery , Humans , Longitudinal Studies , Male , Middle Aged , Nutrition Disorders/complications , Nutritional Status , Surveys and Questionnaires
15.
J Nucl Med ; 41(12): 1999-2010, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11138685

ABSTRACT

UNLABELLED: A phase I therapy study was conducted to determine the safety, maximum tolerated dose (MTD), pharmacokinetics, dosimetry, immunogenicity, and therapeutic potential of 186Re-labeled anti-CD44v6 chimeric monoclonal antibody (cMAb) U36 in patients with squamous cell carcinoma of the head and neck (HNSCC). The potential of a diagnostic study with 99mTc-cMAb U36 to predict the biodistribution of 186Re-cMAb U36 was evaluated. METHODS: Thirteen patients with recurrent or metastatic HNSCC were given 750 MBq 99mTc-cMAb U36 (2 mg) followed 1 wk later by a single dose of 186Re-cMAb U36 (12 or 52 mg) in radiation dose-escalating steps of 0.4, 1.0, and 1.5 GBq/m2. After each administration, planar and SPECT images were obtained, and the pharmacokinetics and development of human antimurine as well as anti-cMAb responses were determined. Radiation absorbed doses to tumor, red marrow, and organs were calculated. RESULTS: Administration was well tolerated, and excellent targeting of tumor lesions was seen in all patients. Dose-limiting myelotoxicity (thrombocytopenia being most prominent) was the only toxicity observed, resulting in grade 4 myelotoxicity in 2 patients treated with 1.5 GBq/m2. The MTD was established at 1.0 GBq/m2, at which a transient grade 3 thrombocytopenia was seen in 1 patient. One patient showed stable disease for 6 mo after treatment at the MTD. The 2 patients with dose-limiting myelotoxicity showed a marked reduction in tumor size. The reduction was of short duration and, therefore, not considered an objective response. Tumor absorbed doses at MTD ranged from 3.0 to 18.1 Gy. Red marrow doses ranged from 20 to 112 cGy (mean, 51 +/- 16 cGy/GBq) and correlated with platelet nadir (r = 0.8; P < 0.01). Pharmacokinetics varied between patients treated at the same dose level and were accurately predicted by the diagnostic procedure. Five patients experienced a human anti-cMAb response, 1 of which was a human antimouse antibody response. CONCLUSION: This study shows that 186Re-cMAb U36 can be safely administered, with dose-limiting myelotoxicity at 41 mCi/m2. The use of cMAb U36 instead of its murine counterpart did not decrease the induction of human antibody responses. The availability of a 99mTc-labeled diagnostic study that can predict the pharmacokinetics of 186Re-cMAb U36 offers the possibility of using such a study for selection of a safe radioimmunotherapy dose.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Carcinoma, Squamous Cell/radiotherapy , Head and Neck Neoplasms/radiotherapy , Radioimmunotherapy , Radioisotopes/therapeutic use , Rhenium/therapeutic use , Aged , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/pharmacokinetics , Antibody Formation , Bone Marrow/radiation effects , Carcinoma, Squamous Cell/secondary , Female , Head and Neck Neoplasms/pathology , Humans , Male , Middle Aged , Neoplasm Recurrence, Local/radiotherapy , Radioimmunotherapy/adverse effects , Radioisotopes/adverse effects , Radioisotopes/pharmacokinetics , Radiotherapy Dosage , Recombinant Fusion Proteins , Rhenium/adverse effects , Rhenium/pharmacokinetics , Thrombocytopenia/etiology
16.
AJNR Am J Neuroradiol ; 20(9): 1727-31, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10543649

ABSTRACT

BACKGROUND AND PURPOSE: The management of the clinically negative neck (NO) remains controversial because the incidence of occult metastases is high and the prognostic difference between elective treatment and a "wait and see" approach remains unclear. This study was undertaken to assess the role of sonographically guided aspiration cytology for the selection of the initial-management strategy for the neck and for the early detection of neck metastases during follow-up of patients with NO. METHODS: Seventy-seven clinically and cytologically confirmed NO patients, who underwent a transoral tumor excision and no neck treatment, were followed up for 1 to 4 years by both palpation and sonographically guided aspiration cytology. RESULTS: Fourteen patients (18%) had recurrent neck tumor; 10 (71%) of these necks were salvaged. Of the 14 neck failures, six were detected before being palpable and nine were detected within 7 months. Eleven of the 19 aspirated tumor-positive nodes had a minimal diameter smaller than 1 cm, and all four patients who eventually died had lymph node metastases larger than 14 mm. CONCLUSION: With sonographically guided aspiration cytology, the risk of missing occult metastases was 18%, which is less than expected after palpation only. Sonographically guided aspiration cytology is an effective technique for following up on the status of the neck after transoral tumor excision, and should be used at frequent intervals if no elective neck treatment is performed.


Subject(s)
Biopsy, Needle/instrumentation , Head and Neck Neoplasms/pathology , Lymphatic Metastasis/pathology , Ultrasonography/instrumentation , Adult , Aged , Female , Follow-Up Studies , Head and Neck Neoplasms/mortality , Head and Neck Neoplasms/surgery , Humans , Lymph Node Excision , Lymph Nodes/pathology , Male , Middle Aged , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/pathology , Neoplasm Staging , Retrospective Studies , Survival Rate
17.
Cancer ; 86(3): 519-27, 1999 Aug 01.
Article in English | MEDLINE | ID: mdl-10430262

ABSTRACT

BACKGROUND: Malnutrition has been recognized as a poor prognostic indicator for cancer treatment-related morbidity and mortality in general, and it is reported to affect 30-50% of all patients with head and neck cancer. In this study, the correlation of nutritional status with 3-year survival was studied prospectively in 64 patients with T2-T4 carcinomas of the head and neck who were treated surgically with curative intent; the surgery was often followed by radiotherapy. METHODS: All patients underwent nutritional screening according to six different parameters on the day prior to surgery. Overall and disease specific survival analyses were performed with a follow-up period of at least 3 years. Survival analyses were performed with the log rank test and the Cox proportional hazards model. RESULTS: Lymph node stage, nonradical resection margins, and occurrence of major postoperative complications were demonstrated to affect disease specific survival for the group as a whole. None of the investigated nutritional parameters were correlated with survival. When men and women were analyzed separately, however, a preoperative weight loss of >5% did have a prognostic value for men. The combination of male gender, preoperative weight loss, and major postoperative complications were related to early death. CONCLUSIONS: Apart from the well-known prognostic parameters lymph node status (T classification) and status of surgical margins, preoperative weight loss and occurrence of major postoperative complications were also found to have a negative effect on the survival of male patients undergoing surgery for advanced head and neck cancer.


Subject(s)
Head and Neck Neoplasms/mortality , Nutrition Disorders/mortality , Nutritional Status , Analysis of Variance , Confidence Intervals , Female , Head and Neck Neoplasms/surgery , Humans , Male , Neoplasm Recurrence, Local/mortality , Postoperative Complications/mortality , Prognosis , Proportional Hazards Models , Prospective Studies , Risk Factors , Sex Factors , Weight Loss
18.
Eur J Nucl Med ; 25(11): 1562-5, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9799354

ABSTRACT

Radioimmunotherapy (RIT) seems to be a realistic option for eradication of minimal residual squamous cell carcinoma of the head and neck (HNSCC), although uptake levels of radiolabelled monoclonal antibodies (MAbs) in tumour tissue vary strongly. The aim of this study was to obtain greater insight into the factors influencing the accumulation of MAbs in HNSCC. Twenty-seven HNSCC patients were injected with radiolabelled MAb E48 or U36 and underwent surgery 2 days after injection. Radioactivity was measured in tumour biopsies taken from the surgical specimen. Uptake levels were correlated with various patient, tumour and MAb characteristics, including age, sex, site, TNM stage, volume as assesssed by computed tomography or magnetic resonance imaging, degree of differentiation, antigen expression of the tumour, the particular MAb that had been injected and the MAb dose. A stepwise regression multivariate analysis showed that tumour volume is the most significant prognostic factor (P=0. 01) for MAb uptake. In conclusion, a significantly higher MAb uptake is found in small tumours as compared to larger tumours. Therefore, RIT may be particularly effective in head and neck cancer patients when used in an adjuvant setting.


Subject(s)
Antibodies, Monoclonal/pharmacokinetics , Head and Neck Neoplasms/metabolism , Head and Neck Neoplasms/pathology , Aged , Female , Head and Neck Neoplasms/diagnostic imaging , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Radionuclide Imaging , Regression Analysis , Technetium Compounds , Tomography, X-Ray Computed
19.
Clin Nutr ; 17(3): 107-11, 1998 Jun.
Article in English | MEDLINE | ID: mdl-10205326

ABSTRACT

Malnutrition is reported to occur in approximately 30% of head and neck cancer patients. Also, impaired immunocompetence is described as a common phenomenon in this patient group. The purpose of this study was to assess the possible relationship between malnutrition and some prognostically important immune parameters in head and neck cancer patients. Thirty-two malnourished (recent weight loss >/= 10%) and 34 well-nourished patients undergoing curative treatment for advanced head and neck cancer were studied prospectively, and six parameters of their immune status (leucocytes, lymphocytes, lymphocyte phenotyping, monocytes, HLA-DR expression on monocytes and serum interleukin-10) were determined on the day of panendoscopy. Reference values for monocytes, HLA-DR expression and interleukin-10 were obtained from 43 healthy controls. Although the number of monocytes was elevated in both patient groups, the HLA-DR expression on these monocytes was significantly lower in the malnourished than in the well-nourished and control groups. Tumor stage, tumor localization, recurrence after initial radiotherapy, age and gender were not correlated to HLA-DR expression. No relationships emerged between nutritional status and lymphocyte subsets. Malnourished head and neck cancer patients show a significantly lower HLA-DR expression on monocytes than well-nourished ones and healthy controls. According to the literature this would imply an increased risk for postoperative complications. Indeed, postoperative complications occur more frequently in malnourished than in well-nourished patients.


Subject(s)
Head and Neck Neoplasms/immunology , Nutrition Disorders/immunology , Nutritional Status , Adult , Female , HLA-DR Antigens/analysis , Humans , Interleukin-10/blood , Killer Cells, Natural , Leukocyte Count , Lymphocyte Count , Male , Middle Aged , Monocytes/immunology , Multivariate Analysis , Prognosis , Weight Loss
20.
Head Neck ; 19(5): 419-25, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9243270

ABSTRACT

BACKGROUND: Malnutrition is reported frequently in head and neck cancer patients. The impact of malnutrition on surgical outcome is not clearly understood. The purpose of this study was to define the usefulness of six different parameters in scoring malnutrition and to determine the nutritional parameter primarily related to postoperative complications. METHODS: Sixty-four patients undergoing major surgery for advanced head and neck cancer were studied prospectively, and six different parameters were used to define malnutrition. Logistic regression was used to relate nutritional parameters to postoperative complications. RESULTS: The parameters applied all identified different aspects of the nutritional status, as malnutrition varied between 20% and 67%. Logistic regression analysis identified a weight loss of more than 10% to be the most prominent predictive parameter for the occurrence of major postoperative complications. CONCLUSIONS: Patients with weight loss more than 10% during the six months before surgery are at a great risk for the occurrence of major postoperative complications.


Subject(s)
Carcinoma, Squamous Cell/surgery , Laryngeal Neoplasms/complications , Laryngeal Neoplasms/surgery , Mouth Neoplasms/complications , Mouth Neoplasms/surgery , Nutrition Disorders/etiology , Pharyngeal Neoplasms/surgery , Deglutition , Female , Humans , Hypopharynx , Male , Middle Aged , Nutritional Status , Oropharynx , Postoperative Complications , Prospective Studies , Regression Analysis , Risk Factors , Weight Loss
SELECTION OF CITATIONS
SEARCH DETAIL